Aiforia Technologies Plc appoints Vice President of Sales for Europe
Aiforia Technologies Plc, Press Release, 5 May 2022 at 09.00 a.m. EEST. Incoming Vice President joins Aiforia from global market leader in digital pathology devices, 3DHISTECH, bringing with him decades of experience holding various executive positions in sales at other companies such as Cisco and Ericsson.
Aiforia has appointed Tamas Regenyi as Vice President of Sales, Europe. The position will be essential to driving Aiforia’s business strategy in the region; focusing on accelerating growth in Aiforia’s established preclinical market in acquiring large customers in the pharmaceutical industry as well as advancing Aiforia’s position in the clinical diagnostics market for pathology.
Mr. Regenyi joins Aiforia most recently from a nearly 10-year career at 3DHISTECH, the first European manufacturer of digital pathology devices and one of the global market leaders. At the company he held the position as the Senior VP of Worldwide Sales and Marketing — bringing with him extensive experience and knowledge in the digital pathology field and complementing Aiforia’s commercial operations.
“Thanks to the tremendous progress in the digitalization of the pathology field, AI is becoming an indispensable everyday tool in the preclinical and clinical process and can add the greatest value ever to the pathologist’s work. I have always been attracted by new territories, the spread of disruptive and transformational technologies,” explains Mr. Regenyi. “I am enthusiastic to join Aiforia, a leader in AI-based image analysis. I feel committed and re-energized to provide the best and most effective mastery of preclinical and clinical artificial intelligence to the pathologists of the world with the Aiforia team!”
“I would like to warmly welcome Tamas to the Aiforia team! His commercial background in global organizations, holding executive positions leading sales, marketing, and sales channel development combined with his high-level industry knowledge of cloud computing, integrated systems, and digital pathology workflows usher in valuable experience to Aiforia and our business goals. We are fortunate to have him on the team,” explains Jukka Tapaninen, CEO of Aiforia Technologies Plc.
Further enquiries
Emma Vehviläinen, CMO, Aiforia Technologies Plc, tel. +358406675204
https://investors.aiforia.com/
Certified Adviser
UB Securities Ltd, tel. +358 9 25 380 225
About Aiforia
Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. Find out more: www.aiforia.com